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LIGHT SENSITIVE ERUPTIONS TREATED WITH ATABRINE
AND CHLOROQUINE
JOHN M. KNOX, M.D., JOHN H. LAMB, Ml)., BEDFORD SHELMIRE, M.D.,AND
ROBERT J. MORGAN, M.D.
In April 1951 a 50-year-old female, a Red Cross worker recently returned
from India, came to one of us (J. M. K.) at Keesler Air Force Base, Biloxi,
Mississippi. While in India she had taken atabrine for its antimalarial action.
During the period that her skin was yellowed by atabrine pigmentation she had
noticed a conspicuous decrease in the severity of a long-standing light-sensitive
eruption, prurigo aestivale. The annoying disease was beginning to reappear
arid she preferred a return of the yellow discoloration to the eruption. Her
response tG atabrine was so noteworthy that later a man 28 years of age with a
plaque-like, light-sensitive eruption of the face was given a similar therapeutic
trial with the same success.
The improvement noted in these two cases, plus the appearance of reports
by Page (la) and others (ib, c, d) on atabrine in discoid lupus erythematosus
encouraged a clinical evaluation of this drug for the treatment of light-sensitive
eruptions.
Black (2), in a report of the use of mepacrine in lupus erythematosus, tested
four patients with actinic dermatitis with this preparation. No description of
the types of dermatitis was recorded. Two female patients were cleared; they had
had the disease each summer for 11 and 30 years respectively. The condition of
the other two patients (who were males) was unaltered by this drug.
DISCUSSION
Figure 1 gives a summary of the 18 cases of various types of solar dermatitis.
The dosage varied among the various investigators reporting, however, all
seemed to achieve the same results. The longest periods of treatment so far on
two cases were for 2 consecutive summers, a total of 9 months and 7 months
respectively. The drug was taken in three instances to ameliorate the "summer
flare" commonly seen in all cases of light sensitivity. The majority of the cases
were treated iii the spring and summer of 1953. No reactions were noted in this
series. However, since this group was collected, in one case of prurigo aestivalis
of 30 years' duration the drug was discontinued because of "chills" and a feeling
of being warm although no fever was recorded. The results of the use of these
drugs have been very encouraging with no failures as yet.
Case no. 4 (L. G.), whose full history was reported in a previous publication
(3), had been on continuous hormone therapy, plus applying a light-screening
ointment (Neo-Afil) ,* for 19 months with only 30 % improvement. His clearing
with atabrine has been the most gratifying of all of the cases and is worth special
mention.
* Neo-Afil—a product of the Texas Pharmacal Company, San Antonio, Texas is an oint-
ment base with menthyl-anthranolate as the screening agent.
Received for publication August 24, 1953.
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Although often beneficial, previous means of treatment, including antihista-
mines, topical sun-screening applications, vitamins and gold sodium thiosulfate,
have been relatively unsatisfactory. The gonadotropic hormone and testosterone
have been curative in many cases of those who have taken the medication for
many months. Treatment is expensive and a large number of patients become
discouraged because of the slowness of improvement. Response to treatment
with atabrine or chloroquine has been quicker and successful in a higher per-
centage of cases. To determine the permanence of the remissions, we must await
time and further summers for study. Their use, though, will be well-established
if they can be taken in the spring and summer of successive years just to prevent
the recurrence of the eruptions.
Toxic and allergic reactions from atabrine and chloroquine have been men-
tioned in other reports. One danger in the use of the drugs in the hot climates
in which these light eruptions are common (Texas, Oklahoma and other south-
western states) is acute s\veat retention. The drug is excreted in the sweat and is
known to interfere in some cases with normal sweating. Blank (4) reports, hov-
ever, that in his wartime experiences those who suffered atrophy of the sweat
glands and sweat retention always had an associated dermatitis. This fact makes
it necessary to be alert for the appearance of any mild dermatitis, i.e., pityriasis
rosea-like, seborrheic or lichenoid dermatoses, while giving these drugs.
COMMENT
Sulzberger (5) suggests that "the mechanism of therapeutic action of atabrine
in lupus erythematosus is still unelucidated. Is it via a local light-screening or
photodynamic mechanism in the skin? Or is it based on antiplasmodial or
antiprotozoal action or action against other infecting agents? Does it act through
metabolic effects? Liver damage? Competition with essential enzyme or coenzyme
systems? Is it conceivably a cortisone-like action, or does it produce some kind
of reticuloendothelial blockade or some specific or nonspecific immunologic
effect?" These same questions can be asked for action of mepacrine and
chloroquine in solar dermatitis.
Ginsburg and Shallenburger (6) and Kierland et al. (7) found that patients
ingesting atabrine demonstrate a fluorescent phenomenon. Using fluorescence
as a method of study, Hermann and Miller (8) conjectured that atabrine has
had an affinity for keratinous structure. Impressively large concentrations of
the drug were found in the nails, hair and horny layer of the epidermis. Excretion
in the sebum, keratin and sweat was observed.
Page found that the time required to administer a minimum erythema dose
of ultraviolet light was increased after mepacrine had been given for 10 days and
that it returned to normal 10 days after discontinuance of the drug. These two
above-named phenomena seem to point to the light-screening effect as the most
plausible theory of its effect on polymorphic light-sensitive eruptions; however,
this may not be the only action. Other factors may be involved, i.e.:
1. Stimulation of the pigment mechanism in the skin.
2. General metabolic effect, that is, stimulus to adrenal or gonads (gonado-
tropic or adrenotropic effects).
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3. Local chemical prevention of changes in the ground substances, that is,
change from collagen to collacin, a constant finding in the dermis of these cases.
If light-screening is the plausible explanation of the action of these drugs in
both lupus erythematosus and polymorphic light-sensitive eruptions, sunlight
must have a much more profound effect on the metabolism of certain human
beings than was previously suspected, and it may be a much greater etiologic
factor in lupus erythematosus than was formerly thought by previous authors
on this subject. However, in spite of a similarity in the effectiveness of these
antimalarial drugs in both lupus erythematosus and solar dermatitis, it is still
our belief that discoid lupus erythematosus and polymorphic light-sensitive
eruptions, although difficult to differentiate microscopically, are distinct clinical
entities. We have not yet seen a case of one disease change into the other.
Chloroquine diphosphate has a somewhat similar chemical structure to
mepacrine although it has one less benzene ring. Even though this chemical does
not produce fluorescence as does mepacrine it appears to be equally as beneficial
as atabrine in both lupus erythematosus and solar dermatitis.
The amount of these agents necessary to prevent actinic dermatitis probably
varies in each case and must be determined by the physician. It is hoped that
small amounts or even traces may be all that are necessary in these light erup-
tions. Osborne (9), in a personal communication, has observed a patient with a
light-urticaria who stays clear on 3 tablets of chioroquine (750 mgm.) but, upon
dropping to 2 tablets daily, begins to break out. Chloroquine may be the drug of
choice in both light-sensitive dermatitis and lupus erythematosus since it is less
toxic and the yellow pigmentation does not occur.
Three patients with discoid lupus erythematosus who had responded well to
atabrine were switched to chioroquine because they had objected somewhat to
the yellowish color of the skin from atabrine. The patients after having been on
chloroquine 2 tablets daily for one month developed a peculiar, tired feeling and
extreme nervousness. Blood count in each case was normal and L.E. cell test
was negative. X-ray examinations of the lungs showed no changes or signs of
tuberculous activity. The chloroquine was discontinued and the patients' nerv-
ous symptoms seem to be improved.
Further reports about chloroquine will be forthcoming because it is being
tried in lupus erythematosus by many dermatologists over the country. One such
report by Goldman et al. (10) of its use in lupus erythematosus agrees with our
above observations.
SUMMARY
1. Improvement was noted in 18 individuals with light-sensitive eruptions
following systemic administration of atabrine or chloroquine.
2. As yet no explanation seems to explain all of the factors in the beneficial
effect of these drugs on patients with actinic dermatitis.
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